OCGN
Ocugen, Inc.
0.39
USD
This page is just a preview of the data found in TrendSpider’s full version
Ocugen, Inc. stock is up 8.03% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 9 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 PUT.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 04 Dec 20:02 | 19 Jan, 2024 | 30.00 | 0 |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis. OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD) and OCU200, is in preclinical development stage.
